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The psychological cost on emotional well-being due to the collateral damage brought
about by COVID-19 in accessing oncological services for breast cancer diagnosis
and treatment has been documented by recent studies in the United Kingdom. The
current study set out to examine the effect of delays to scheduled oncology services
on emotional and cognitive vulnerability in women with a breast cancer diagnosis in
Iran, one of the very first countries to be heavily impacted by COVID-19. One hundred
thirty-nine women with a diagnosis of primary breast cancer answered a series of
online questionnaires to assess the current state of rumination, worry, and cognitive
vulnerability as well as the emotional impact of COVID-19 on their mental health. Results
indicated that delays in accessing oncology services significantly increased COVID
related emotional vulnerability. Regression analyses revealed that after controlling for the
effects of sociodemographic and clinical variables, women’s COVID related emotional
vulnerability explained higher levels of ruminative response and chronic worry as well
as poorer cognitive function. This study is the first in Iran to demonstrate that the
effects of COVID-19 on emotional health amongst women affected by breast cancer
can exaggerate anxiety and depressive related symptoms increasing risks for clinical
levels of these disorders. Our findings call for an urgent need to address these risks
using targeted interventions exercising resilience.
Keywords: breast cancer, COVID-19, emotional vulnerability, cognitive function, psychological health
INTRODUCTION
Iran was one of the first countries to be significantly affected by the coronavirus disease (SARS-
CoV-2; COVID-19) outbreak shortly after China. The rapid spread of the virus throughout the
country caused profound psychological fear (Pakpour and Griffiths, 2020), anxiety (Moghanibashi-
Mansourieh, 2020) and resulted in many restrictions to the regular medical health care services
available including, cancer clinics.
Breast cancer is the most common cancer in Iran with the mean age of 49.84 (Nafissi et al., 2018)
and an incidence rate of 28.3 per 100,000 in women (Sharifian et al., 2015). Throughout diagnosis,
treatment and well into survivorship, women require continuous access to multiple healthcare
services (Dietz et al., 2020).
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There are no published studies on the impact of COVID-19
on rates of recurrence and survival in breast cancer. However,
a recent report has revealed a series of temporary modifications
have been made to the approved breast cancer care guidelines in
Iran to reserve medical resources for individuals with COVID-19
(Shahi et al., 2020). Studies now show that the United Kingdom
has witnessed a 15% decline in breast cancer referrals during
2020 compared to a similar period in 2019 (Gathani et al.,
2021), with estimations for significant reductions in survival
rates and increased mortality as a result of the collateral
damage brought about by COVID-19 on cancer treatment
(see Maringe et al., 2020). These changes in circumstances
created by the COVID-19 outbreak has imposed a great deal
of distress and trauma on healthcare providers who have been
forced to make unprecedented clinical decisions and handle
reorganization, including treatment allocation and modification
(Romeo et al., 2020).
In a recent meta-analysis that investigated the survival rate
of women with primary breast cancer, both age at diagnosis
and stage of breast cancer independently affected survival rate
(Maajani et al., 2019). Studies show that delays in early diagnosis
and disruption to active treatment can severely reduce survival
rates (Smith et al., 2013). In younger women aged <45 years,
breast cancer is more aggressive with a less favorable prognosis,
and worse mortality rate than in older women (Radecka and
Litwiniuk, 2016). It is also well documented that younger women
diagnosed with breast cancer not only suffer from long term
physical problems such as fatigue, insomnia, joint pain, and
hot flushes but also tolerate radical early menopause and loss
of fertility caused by chemotherapy and endocrine therapies
(Rosenberg and Partridge, 2013; Anastasiadi et al., 2017) such
as Tamoxifen. Given, the high prevalence of younger women
(<45 years) diagnosed with aggressive breast cancer in Iran the
disruption to available healthcare service caused by the pandemic
could have a profound effect on breast cancer mortality over
the next few years.
A large and growing body of literature substantiates that
cancer-related cognitive impairments (CRCI) (see Ahles and
Root, 2018, for a review) can exist for many years post active
treatment substantially affecting the quality of life. Self-reported
cognitive function plays a critical role in determining emotional
well-being in women with breast cancer (Chapman et al., 2019).
Cognitive mechanisms such as rumination and worry increase an
individual’s vulnerability to developing distinct and overlapping
forms of emotional disorders such as anxiety and depression
(see Koster et al., 2017, for a review). In a recent meta-analysis
by Wang et al. (2020), which included 282,203 breast cancer
patients, it was found that depression and anxiety independently
predicted all-cause mortality and cancer recurrence, respectively.
It is imperative therefore that the risk factors for these disorders
are understood. Rumination is conceptualized as repetitive
negative affective thoughts focused on current or past events
(Nolen-Hoeksema, 2000), and worry is identified by involuntary
thoughts about possible future threats (Borkovec et al., 1983).
Whilst intrusive rumination has a critical role in the initiation
and maintenance of Post Traumatic Stress Disorder (PTSD)
symptoms in women living with a diagnosis of breast cancer
(Ogińska-Bulik and Michalska, 2020), worry has been shown
to be more strongly associated with depression and anxiety
in cancer survivors (Brown et al., 2018). Ruminative thinking
can jeopardize well-being in patients diagnosed with primary
breast cancer (Liu et al., 2020). Further, a recent study by
Renna et al. (2020) indicated that both rumination and worry
increase cancer-related distress and indirectly result in more
self-reported physical complaints in women with a history of
breast cancer. It is, therefore, not surprising that disruptions
in medical services due to the COVID-19 outbreak could not
only result in more severe physical conditions in breast cancer
patients but also lead to more acute emotional distress and
worse cognitive impairment (Swainston et al., 2020). It is also
a critical risk for developing PTSD symptoms (Romeo et al.,
2020).
The current study aimed to firstly investigate the impact
of delays in accessing medical care on levels of COVID
related emotional vulnerability (COVID-EMV). Secondly, by
considering the critical role that age plays in treatment outcomes
in cancer patients (Fernandes-Taylor et al., 2015), we investigated
the impact of age on rumination, worry, cognitive function,
and COVID-EMV. We then examined the relationship between
COVID-19 related emotional vulnerability (COVID-EMV),
rumination, worry, and cognitive function whilst allowing for
clinical and sociodemographic variables (education, grade, age
at diagnosis, time since treatment finished, and health co-
morbidity).
Firstly, we predicted that women who experienced delays
in accessing medical care would report higher COVID-EMV
compared to women who experienced no disruption. Secondly,
we predicted that younger women (≤45 years old a cut-
off recommended by Breast cancer in younger women, 2018)
would experience more severe rumination, pathological worry,
cognitive dysfunction and COVID-EMV compared to older
women (>45 years old). We expected that after allowing for a
range of clinical and sociodemographic variables COVID-EMV
would significantly predict higher levels of trait vulnerability to
emotional disorders as documented through higher rumination,
worry and poorer cognitive function.
MATERIALS AND METHODS
Design
A cross-sectional approach was used to investigate the impact
of the COVID-19 outbreak on the emotional well-being and
cognitive function of women living with a breast cancer diagnosis
in Iran. Participants were asked to respond to a series of online
questionnaires assessing their demographic characteristics such
as type of breast cancer, medical history, level of rumination,
pathological worry and cognitive function.
Participants
A total of 139 women with a diagnosis of primary breast cancer
(Mean Age = 45; SD = 9.60, Mean Age at Diagnosis = 42,
SD = 9.38) were voluntarily recruited via multiple sources:
online advertisement placed on social media platforms including,
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Instagram pages related to breast cancer and COVID-19 (such
as @Coronavirus_breast_cancer owned by researchers) and the
cancer research center of Imam Khomeini Hospital in Tehran.
The primary inclusion criteria for participants was a diagnosis of
primary breast cancer. Participants were recruited between May
9th 2020 and May 29th 2020, during Iran’s first pandemic peak.
Materials
Demographic and Clinical Questionnaire (DQ)
To collect participant’s information regarding their breast cancer
history and sociodemographic characteristics we designed a 27
item self-report questionnaire (see Table 1).
Functional Assessment of Cancer Therapy-Cognitive
Scale (FACT-Cog)
The third version of the FACT-Cog (Wagner et al., 2009) is a 37-
item questionnaire, using a 5-point Likert-scale, with a total score
ranging from 0 to 148. It consists of four subscales: perceived
cognitive impairments (PCI, 20 items), comments from others
(4 items), perceived cognitive ability (PCA, 9 items), and impact
on quality of life (QoL, 4 items). This questionnaire is designed
to measure cognitive complaints and abilities in the past 7 days.
Higher scores in all subscales indicate better cognitive function
and quality of life. This highly reliable questionnaire has been
widely used in previous breast cancer studies (Von Ah and
Tallman, 2015; Janelsins et al., 2017; Vardy et al., 2019). A Farsi
version of this questionnaire with excellent internal consistency
was used in this study (α = 0.97).
Rumination Response Scale (RRS)
The rumination scale includes 22 items that assess the depressive
rumination experienced over the last 7 days. Each item is rated on
a Likert scale ranging from 1 (almost never) to 4 (almost always),
with total scores ranging from 22 to 88. Higher scores indicate
more rumination. The Internal consistency for the Farsi version is
α = 0.88 (Bagherinezhad et al., 2010). This reliable questionnaire
has been used in many cancer research studies in Iran (Heidarian
et al., 2016). The internal consistency in the present study was
excellent (α = 0.96).
Penn State Worry Questionnaire (PSWQ)
The PSWQ is a 16-item inventory with a 5-point Likert scale
(1 = Not at all typical of me, 5 = very typical of me), higher
scores represent a greater level of pathological worry (PSWQ
total score ranges from 16 to 80). The PSWQ is a widely
used measure in breast cancer research (Ghanavati et al., 2018;
Swainston and Derakshan, 2018; Chapman et al., 2020). In this
study, a Farsi version with a good internal consistency was used
(α = 0.88) (Dehshiri et al., 2010). Internal consistency in the
current study was 0.91.
Modified Self-Report-Generated Charlson
Comorbidity (CCI)
The modified version of the Charlson Comorbidity Index with
nine comorbidity items was used to measure pre-existing health
conditions. All participants were asked to respond to this
questionnaire based on their knowledge of their current medical
TABLE 1 | Participant demographics, clinical characteristics, and
psychiatric history.
Demographic variable N = 139 (%)
Current age Mean = 45.86 years (Min = 17, Max = 75)
Age at diagnosis Mean = 42.43 years (Min = 16, Max = 74)
Time on treatment Mean = 12.76 months (Min = 1, Max = 146)
Time since treatment finished Mean = 27.32 months (Min = 0, Max = 199)
Age category
Less than or equal to 45 71 (51.1%)
More than 45 68 (48.9%)
Education
8 Years or less 17 (12.2%)
Diploma or college 38 (27.3%)
Undergraduate 66 (47.5%)











Active treatment 26 (18.7%)
Grade
Grade I 30 (21.6%)
Grade II 54 (38.8%)
Grade III 55 (39.6%)
Lymph node involvement 63 (45.3%)






Mastectomy and lumpectomy 3 (2.2%)
Endocrine therapy 74 (53.2%)
Delays in accessing medical care 38 (27.3%)
Delays in surgery 4 (2.9%)
Delays in treatment 34 (24.5%)
conditions. These nine items are given independent weighted
values (i.e., HIV illness or AIDS = 6, Diabetes = 2). The CCI
total score ranges from 0 to 19 by the summation of these values.
A higher score specifies more chronic comorbidity. The CCI has
been used in previous research to measure comorbidity in women
diagnosed with breast cancer (Ording et al., 2013; Fu et al., 2015;
Soleymanian and Ghaziani, 2018). In this study, the summed
score of CCI was used.
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COVID-19 Impact Questions
Twenty-three individual items were translated from Swainston
et al. (2020) and Chapman et al. (2020) to assess the impact of
the COVID-19 outbreak in women living with breast cancer in
Iran. Specifically, questions examined the impact of COVID-19
on current emotional (psychological) vulnerability as well as the
history of the COVID-19 symptoms (i.e., high temperature/fever,
continuous cough).
To measure the emotional impact of COVID-19, a composite
score was formed by combining the five psychological related
items (i.e., the outbreak led me to feel more: (1) anxious,
(2) upset, (3) fearful than usual or has the outbreak made
you feel less: (4) in control or (5) less confident than usual).
This composite COVID emotional vulnerability (COVID-EMV)
score showed an excellent internal consistency (α = 0.90) (see
supplementary Material for more detailed factor analysis and
COVID-EMV correlations).
In the COVID-19 symptoms section, personal experience of
COVID-19 symptoms was assessed by checking the COVID-19
symptoms confirmed by World Health Organsiation (2020) (high
temperature/fever, continuous cough, shortness of breath, chest
pain or pressure, sore throat, sneezing or runny nose, loss of smell
and/or taste, bluish lips or face or new confusion or inability to
arouse). In addition, isolation status and any change in cancer
treatment plan due to the outbreak were individually asked.
Procedure
Before completing the online questionnaires, participants were
asked to provide a telephone number to receive a phone call from
the researchers to become familiar with the structure of the study
and its overall aim. Once the participant agreed to participate in
the research, they received the research URL code via an email
to access the battery of self-report questionnaires. Following
completing the online consent form, they were directed to the
DQ, CCI, FACT-Cog, RRS, PSWQ and finally the COVID-19
Impact Questions. At the end of the session, participants were
thanked for their time and effort, with 500,000 Rials transferred
to their bank account. Before commencing the study, ethical
approval was obtained from the Research Ethics Committee of
the Kharazmi University (Ethic code: IR.KHU.REC.1399.002).
Statistical Analysis
All analyses were carried out using R, version 4.0.3. Descriptive
statistics were calculated for sociodemographic characteristics
and history of breast cancer (see Table 1). Independent t-tests
were conducted to explore the impact of delays in accessing
medical care (i.e., delay vs. no delay) on COVID-EMV as
well as the effects of age on rumination, worry, cognitive
function and COVID-EMV (see Table 2). Cohen’s d effect sizes
were calculated.
Hierarchical regression analyses were run on the total sample
size (N = 139) to assess the relationship between COVID-
EMV and rumination (see Table 3), pathological worry (see
Table 4), and cognitive ability (see Table 5). On the first step, five
factors were added including, education, grade, age at diagnosis,
time since treatment finished, and CCI. COVID-EMV was then
entered on the second step.
TABLE 2 | t-test results in comparing the age groupsa.
Age ≤ 45 (n = 71) Age > 45 (n = 68)
Mean (SD) Mean (SD) t P
Rumination 49.49 (16.71) 44.25 (14.01) 2.00 0.05
Pathological worry 50.68 (14.38) 51.12 (13.85) −0.18 0.85
Cognitive function 106.25 (26.43) 110.16 (28.12) −0.84 0.40
COVID-EMV 13.37 (5.55) 10.97 (5.08) 2.65 0.01
aRumination: higher score = more rumination; Pathological worry: higher
score = greater worry; Cognitive function: higher score = better cognitive function;
COVID-EMV: higher score = more emotional vulnerability.
TABLE 3 | Hierarchical regression analyses for the predictors of rumination.
b SE B β t p
Step 1
(Intercept) 62.53 (43.46, 81.60) 9.64 6.49 0.00
Education −1.78 (−.94, 1.39) 1.60 −0.10 −1.11 0.27
Grade 2.19 (−1.23, 5.60) 1.73 0.11 1.27 0.21
Age at
diagnosis













(Intercept) 35.39 (18.56, 52.22) 8.51 4.16 0.00
Education −1.26 (−3.84, 1.32) 1.30 −0.07 −0.96 0.34
Grade 0.75 (−2.06, 3.55) 1.42 0.04 0.53 0.60
Age at
diagnosis








2.29 (0.50, 4.08) 0.91 0.18 2.53 0.01





Preliminary analyses were conducted to ensure no violation
of the assumptions of normality, linearity, and homoscedasticity.
Using analysis of standardized residual, no outliers were found
(Rumination: std Residual Min =−2.64, std Residual Max = 2.84,
std deviation = 0.98; Worry: std Residual Min = −2.11, std
Residual Max = 2.73, std deviation = 0.98; Perceived cognitive
function: std Residual Min = −3.16, std Residual Max = 1.98, std
deviation = 0.98). Post hoc analyses were conducted using Cohen’s
f 2 (Ben-Shachar et al., 2020) and a significance of 0.05.
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TABLE 4 | Hierarchical regression analyses for the predictors of
pathological worry.
b SE B β t p
Step 1
(Intercept) 48.32 (30.46, 66.18) 9.03 5.35 0.00
Education −1.53 (−4.49, 1.44) 1.50 −0.09 −1.02 0.31
Grade 1.64 (−1.56, 4.84) 1.62 0.10 1.02 0.31
Age at
diagnosis













(Intercept) 26.71 (9.86, 43.57) 8.52 3.14 0.01
Education −1.11 (−3.70, 1.47) 1.31 −0.07 −0.85 0.40
Grade 0.50 (−2.31, 3.31) 1.42 0.03 0.35 0.73
Age at
diagnosis








−0.04 (−1.83, 1.76) 0.91 −0.01 −0.04 0.97





There was no missing data for any of the questionnaires used
in the current study.
RESULTS
Data was collected from 139 women with a primary breast
cancer diagnosis (mean age = 45.86, SD = 9.60; mean age at
diagnosis = 42.43, SD = 9.38). A total of 38 women (27.3%) had
been impacted by disruption to their scheduled medical services
[delay in surgery (2.9%) and delay in treatment (24.5%)]. Only 32
women (23%) reported that they had shown COVID-19 related
symptoms (7.9% of symptoms reported were fever and/or cough).
109 participants (78.4%) revealed that they had decided to self-
isolate themselves to reduce the risk of contracting the virus.
None of the participants reported that they had received a clinical
diagnosis of COVID-19.
Effects of Delay
Of the 139 women who completed the questionnaire, 38 (27.3%)
experienced delays in accessing medical care (4 experienced
delays to surgery and 34 experienced delays to treatment). This
TABLE 5 | Hierarchical regression analyses for the predictors of perceived
cognitive function.
b SE B β t p
Step 1
(Intercept) 91.88 (58.67, 125.08) 16.79 5.47 0.00
Education 4.31 (−1.20, 9.82) 2.79 0.14 1.55 0.12
Grade −3.57 (−9.52, 2.38) 3.01 −0.10 −1.19 0.24
Age at
diagnosis













(Intercept) 123.05 (89.73, 156.38) 16.85 7.30 0.00
Education 3.72 (−1.39, 8.82) 2.58 0.12 1.44 0.15
Grade −1.92 (−7.48, 3.63) 2.81 −0.05 −0.69 0.49
Age at
diagnosis








−5.10 (−8.64, −1.55) 1.79 −0.23 −2.84 0.01





group reported significantly more COVID-EMV (M = 13.66,
SD = 5.99) compared to those who reported no delays (M = 11.64,
SD = 5.14; t (137) = 1.97, p = 0.05, d = 0.37]. Women who
had experienced delays reported significantly more pathological
worry (M = 54.79, SD = 13.39) compared to those who
experienced no delays (M = 49.43, SD = 14.11; t (137) = 2.02,
p = 0.04, d = 0.39]. These effects were not visible for rumination
scores [t (137) = 1.28, p = 0.20, d = 0.24] between women in
the delayed group (M = 49.68, SD = 13.44) and the no-delay
group (M = 45.89, SD = 16.30). There were no group differences
on perceived cognitive ability (delayed group M = 103.16,
SD = 27.39; no delay group: M = 110.05, SD = 27.08; t
(137) =−1.33, p = 0.18, d = 0.2).
Effects of Age
As shown in Table 2, younger women (current age ≤ 45 years)
reported significantly more rumination (M = 49.49, SD = 16.71)
than older women (M = 44.25, SD = 14.01; t (137) = 2.00,
p = 0.05, d = 0.34). Younger women also reported significantly
more COVID-EMV (M = 13.37, SD = 5.55) compared with older
women (M = 10.97, SD = 5.08; t (137) = 2.65, p = 0.01, d = 0.45).
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There were no significant differences in pathological worry (t
(137) =−0.18, p = 0.85, d = 0.03) for younger women (M = 50.68,
SD = 14.38) and older women (M = 51.12, SD = 13.85), and also
in cognitive function (t (137) =−0.84, p = 0.40, d = 0.14) between
younger women (M = 106.25, SD = 26.43) and older women
(M = 110.16, SD = 28.12).
Impact of Covid-19 Related Distress on
Emotional Vulnerability
Rumination
On Step 1 of the hierarchical regression analysis, education,
grade, age at diagnosis, time since treatment finished, and
CCI accounted for 9.4% of the variance (see Table 3). When
COVID-EMV was added on Step 2, it significantly predicted
increased variance in rumination with an R2 (change) of 31%
[t (132) = 8.28, p < 0.001], with higher COVID-EMV meeting
higher rumination. CCI was also a significant predictor on the
second step [t (132) = 2.53, p = 0.01]. Cohen’s f 2 = 0.52 and
achieved statistical power (1-ß err prob) was 0.99.
Pathological Worry
When predicting worry the demographic variables entered
on Step 1 accounted for a small 2.2% variance in women’s
pathological worry. The explained variance was increased to 26%
when COVID-EMV was entered in step two (t (132) = 6.58,
p < 0.001). Greater COVID-EMV met with a higher level of
worry. COVID-EMV was the only significant predictor on the
second step. Cohen’s f 2 = 0.33 and achieved statistical power (1-ß
err prob) was 0.99.
Cognitive Function
When predicting cognitive function our predictors on Step 1
included education, grade, age at diagnosis, time since treatment
finished, and CCI, which collectively explained 9.7% of the
variance in cognitive function. On the second step, COVID-EMV
predicted significant variance in cognitive function with an R2
(change) of 13.3% [t (132) = −4.80, p < 0.001] such that lower
cognitive function met a higher level of COVID-EMV. CCI was
also a significant predictor on the second step [t (132) = −2.84,
p = 0.01]. Cohen’s f 2 = 0.17 and achieved statistical power (1-ß
err prob) was 0.99.
Checks for violation of assumptions showed collinearity
(Tolerance > 0.1, VIF < 10), independent error
(Rumination: Durbin–Watson = 1.78; Pathological Worry:
Durbin–Watson = 1.97; Perceived Cognitive Function: Durbin–
Watson = 1.99) normality and homogeneity of variance and
linearity were met for rumination, pathological worry and
cognitive function.
DISCUSSION
The present study investigated the effect of the emotional distress
caused by COVID-19 outbreak on levels of rumination and worry
as well as cognitive function in women living with primary
breast cancer in Iran. We found that those who experienced
delays in accessing medical care had higher levels of COVID-
19 related emotional distress and pathological worry. This
finding is consistent with that of Swainston et al. (2020) who
found that this disruption resulted in more general anxiety,
depression and COVID-19 related emotional vulnerability in
the United Kingdom’s breast cancer population. It suggests
that factors associated with the COVID-19 pandemic (i.e.,
delays in surgery and treatment) have led to more excessive
COVID-19 related emotional distress and worry in the breast
cancer population.
Of focal importance we found that younger women (≤45 years
old) reported more severe rumination (i.e., more repetitive
negative thoughts) and COVID-EMV (i.e., more fear about
cancer than usual feeling less control over their health) compared
to older women (>45 years old). These findings could be
partly driven by the fact that younger women are at a greater
risk women are at a greater risk of having more aggressive
tumor characteristics (i.e., Her2+), persistent fear of recurrence,
metastasis and premature mortality (Anders et al., 2009; Assi
et al., 2013; Champion et al., 2014; Lee et al., 2015) compared to
older women with the same diagnosis. Previous studies have also
highlighted that younger women often have less social support
(Champion et al., 2014) and more responsibilities including
young children and financial obligations. It is plausible that
a combination of these clinical and social factors is driving
the younger women’s more persistent (or repetitive) negative
thoughts and COVID-EMV in our study as they likely have
greater concerns about the impacts of COVID-19 on their long-
term survivorship and the impact the outcomes could have
on their family. Based on our findings we recommend that
further qualitative research is conducted to explore the types
of negative thoughts or concerns (i.e., recurrence) younger
women are encountering as this will allow more informed
support to be provided.
The findings from our study also indicate that self-reported
physical illness comorbidity (as measured by CCI) is predictive of
the severity of rumination and cognitive impairment experienced
by women with breast cancer. This result is consistent with
studies that have shown that poorer self-reported physical
health has a significant association with rumination (Thomsen
et al., 2004). These underlying physical conditions such as
cardiovascular disease and diabetes are a crucial prognostic factor
in early breast cancer (Land et al., 2012).
Finally, we found that after controlling for several clinical
and sociodemographic variables such as education, grade, age
at diagnosis, time since treatment finished, and comorbidity
index, COVID-19 related emotional distress (COVID-EMV) was
a notable predictor for more rumination, worry and cognitive
impairment in women with a history of primary breast cancer.
This result can be explained by the fact that women are
experiencing an increasing number of negative feelings such as
a sense of loss of control over their health due to the COVID-
19 pandemic, with the added stress of disruptions to oncological
services resulting in greater COVID-19 emotional vulnerability.
Such negative feelings could be provoking cognitive impairment
by creating an internal distraction and a greater level of worry and
rumination which if not targeted early could then progress into
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clinical emotional disorders including anxiety and depression.
Rumination is known to play a critical role in the development
and maintenance of affective disorders (i.e., anxiety, depression
or mixed anxiety and depression) (Nolen-Hoeksema, 2000).
Emotional distress in breast cancer patients has been associated
with unfavorable outcomes in treatment compliance (Greer et al.,
2008), which might negatively impact on disease progression and
mortality rate (Satin et al., 2009). With depression and anxiety
both predicting cancer recurrence and cancer specific mortality
in breast cancer patients it becomes imperative to address the
cognitive and emotional vulnerability experienced by women as
a result of COVID-19 to avoid any further detrimental effects on
their long-term health.
The present study adds to the growing body of research
indicating that groups with underlying health conditions are
more likely to suffer adverse outcomes due to the COVID-
19 outbreak (Jiang et al., 2020; Lai et al., 2020). Our results
also extend those of Swainston et al. (2020), who also
found that delays in treatment resulted in more COVID-
EMV, and also worse COVID-EMV in primary breast cancer
predicting more emotional (psychological) distress and cognitive
impairments. Further studies which focus on the underlying
factors in developing emotional and cognitive problems in
the breast cancer population will need to be undertaken.
Investment in online interventions such as cognitive training
that have successfully reduced anxiety and rumination in breast
cancer survivors (Swainston and Derakshan, 2018) is highly
recommended. In addition, governmental efforts can target the
development of applications designed to assist women with
breast cancer to record and monitor their symptoms on a
daily basis so that with online communication patients can
relay information to healthcare professionals who in turn can
identify those at higher risk of developing clinical levels of
anxiety and depression as well as other physical conditions
needing attention.
LIMITATION
Our study is limited due to the cross-sectional design. Data
were collected at a one-time point via a series of online
questionnaires. Approximately 60% of our participants had
higher education levels, which means that these findings may
not be fully representative of Iran’s breast cancer population.
Secondly, delayed treatment did not specify the amount of time
lost due to delays mainly because participants were unaware of
any rescheduling to their treatment at the time the study was
conducted. Finally, our study focused on women with a primary
diagnosis of breast cancer. Future studies need to investigate the
collateral damage brought about by COVID-19 on the mental
well-being of women with metastatic breast cancer who are at a
greater risk of clinical vulnerability to depression.
CONCLUSION
The most prominent finding to emerge from this study is that
women with breast cancer are at risk of experiencing more
rumination, worry and cognitive impairment due to COVID-
19 related emotional distress. The critical role of worry and
rumination in the maintenance of depression, anxiety and
PTSD, as well as the role of depression and anxiety in cancer
recurrence and mortality, indicate the possible risks facing
women with breast cancer as a result of the COVID-19 outbreak.
This study has highlighted the realities we continue to face
from the psychological impact of the outbreak in vulnerable
populations and individuals suffering from underlying health
conditions. Further work can investigate the long-term impact
of the COVID-19 pandemic on women living with breast
cancer who will benefit from access to cognitive and emotional
health interventions.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Jamshid Shanbehzadeh, Department of
Electrical and Computer Engineering, Kharazmi University, I.
R. Iran Azizollah Habibi Department of Chemistry, Kharazmi
University, Tehran, Iran; Mehdi Abbasi Sarmadi, Faculty of
Law and Political Sciences, Kharazmi University, Tehran, Iran;
Ali Akbar Imani, Department of Islamic Studies, Faculty of
Literature and Humanities, Tehran, Iran; Mahdi Akbarzadeh,
The Cellular and Molecular Endocrine Research Center, Shahid
Beheshti University of Medical Sciences, Tehran, Iran; Mehdi
Tehrani-Doost, Department of Psychiatry, Tehran University of
Medical Sciences, Tehran, Iran; Fatemeh Javaheri, Department
of Sociology, Faculty of Literature and Humanities, Kharazmi
University, Tehran, Iran; Jafar Hasani, Department of Clinical
Psychology, Faculty of Psychology and Education, Kharazmi
University, Tehran, Iran. Online informed consent to participate
in this study was provided by the participant at the start of the
study.
AUTHOR CONTRIBUTIONS
BC, EG, VM, and ND: research question and study design. AM:
funding. MC and VM: preparation of data and data collection.
MC, VM, and BC: drafting initial version of manuscript and
drafting final version of manuscript. All authors contributed to
the analysis plan, statistical analysis, and critical review of early
and final versions of manuscript.
FUNDING
AM was in receipt of an Iranian Center of Excellence in Stress and
Health grant from Kharazmi University (2020-1-kr).
Frontiers in Psychology | www.frontiersin.org 7 May 2021 | Volume 12 | Article 663310
fpsyg-12-663310 June 1, 2021 Time: 15:32 # 8
Choobin et al. COVID-19 in Breast Cancer
ACKNOWLEDGMENTS
We thank Drs. Maryam Tabatabaian and Mojtaba Ghadyani for
helping us in this project and finally, we thank all of the women
for their time and support.
SUPPLEMENTARY MATERIAL




Ahles, T. A., and Root, J. C. (2018). Cognitive effects of cancer and cancer
treatments. Annu. Rev. Clin. Psychol. 14, 425–451. doi: 10.1146/annurev-
clinpsy-050817-084903
Anastasiadi, Z., Lianos, G. D., Ignatiadou, E., Harissis, H. V., and Mitsis, M.
(2017). Breast cancer in young women: An overview. Updates Surg. 69, 313–317.
doi: 10.1007/s13304-017-0424-1
Anders, C. K., Johnson, R., Litton, J., Phillips, M., and Bleyer, A. (2009).
Breast cancer before age 40 years. Semin. Oncol. 36, 237–249. doi: 10.1053/j.
seminoncol.2009.03.001
Assi, H. A., Khoury, K. E., Dbouk, H., Khalil, L. E., Mouhieddine, T. H., and El
Saghir, N. S. (2013). Epidemiology and prognosis of breast cancer in young
women. J. Thoracic Dis. 5(Suppl. 1), S2–S8. doi: 10.3978/j.issn.2072-1439.2013.
05.24
Bagherinezhad, Fadardi, and Tabatabaee. (2010). Relationship between rumination
and depression in a sample of iranian students. Stud. Educat. Psychol. 10, 21–38.
Ben-Shachar, M., Lüdecke, D., and Makowski, D. (2020). effectsize: Estimation of
Effect Size Indices and Standardized Parameters. J. Open Source Softw. 5:2815.
doi: 10.21105/joss.02815
Borkovec, T. D., Robinson, E., Pruzinsky, T., and DePree, J. A. (1983). Preliminary
exploration of worry: Some characteristics and processes. Behav. Res. Therapy
21, 9–16. doi: 10.1016/0005-7967(83)90121-3
Breast cancer in younger women (2018). Breast Cancer Now. Available online
at: https://breastcancernow.org/information-support/facing-breast-cancer/
breast-cancer-in-younger-women
Brown, S. L., Hope-Stone, L., Heimann, H., Damato, B., and Salmon, P. (2018).
Predictors of anxiety and depression 2 years following treatment in uveal
melanoma survivors. Psycho Oncol. 27, 1727–1734. doi: 10.1002/pon.4715
Chapman, B., Swainston, J., Grunfeld, E. A., and Derakshan, N. (2020). COVID-19
Outbreak effects on job security and emotional functioning amongst women
living with breast cancer. Front. Psychol. 11:582014. doi: 10.3389/fpsyg.2020.
582014
Champion, V. L., Wagner, L. I., Monahan, P. O., Daggy, J., Smith, L., Cohee, A.,
et al. (2014). Comparison of younger and older breast cancer survivors and age-
matched controls on specific and overall quality of life domains: Comparison
of Breast Cancer Survivors. Cancer 120, 2237–2246. doi: 10.1002/cncr.2
8737
Chapman, B., Helmrath, S., and Derakshan, N. (2019). Perceived cognitive
functioning and its influence on emotional vulnerability in breast cancer.
Health Psychol. Open 6:205510291987166. doi: 10.1177/20551029198
71661
Dehshiri, G. H. R., Golzari, M., Borjali, A., and Sohrabi, F. (2010). Psychometrics
Particularity of Farsi Version of Pennsylvania State Worry Questionnaire for
College Students. J. Clin. Psychol. 1, 67–75.
Dietz, J. R., Moran, M. S., Isakoff, S. J., Kurtzman, S. H., Willey, S. C., Burstein,
H. J., et al. (2020). Recommendations for prioritization, treatment, and triage
of breast cancer patients during the COVID-19 pandemic. The COVID-19
pandemic breast cancer consortium. Breast Cancer Res. Treat. 181, 487–497.
doi: 10.1007/s10549-020-05644-z
Fernandes-Taylor, S., Adesoye, T., and Bloom, J. R. (2015). Managing psychosocial
issues faced by young women with breast cancer at the time of diagnosis and
during active treatment. Curr. Opin. Support. Palliat. Care 9, 279–284. doi:
10.1097/SPC.0000000000000161
Fu, M., Axelrod, D., Guth, A., Cleland, C., Ryan, C., Weaver, K., et al.
(2015). Comorbidities and Quality of Life among Breast Cancer Survivors:
A Prospective Study. J. Personaliz. Med. 5, 229–242. doi: 10.3390/jpm5
030229
Gathani, T., Clayton, G., MacInnes, E., and Horgan, K. (2021). The COVID-19
pandemic and impact on breast cancer diagnoses: What happened in England
in the first half of 2020. Br. J. Cancer 124, 710–712. doi: 10.1038/s41416-020-
01182-z
Ghanavati, A., Bahrami, F., Godarzi, K., and Rozbahani, M. (2018). Effectiveness of
compassion-based therapy on rumination and concern of women with breast
cancer. Health Psychol. 7, 152–168.
Greer, J. A., Pirl, W. F., Park, E. R., Lynch, T. J., and Temel, J. S. (2008).
Behavioral and psychological predictors of chemotherapy adherence in patients
with advanced non-small cell lung cancer. J. Psychosomat. Res. 65, 549–552.
doi: 10.1016/j.jpsychores.2008.03.005
Heidarian, A., Zahrakar, K., and Mohsenzade, F. (2016). The Effectiveness of
Mindfulness Training on Reducing Rumination and Enhancing Resilience in
Female Patients with Breast Cancer: A Randomized Trial. Iran J. Breast Dis. 9,
52–59.
Janelsins, M. C., Heckler, C. E., Peppone, L. J., Mohile, S. G., Mustian, K. M.,
Ahles, T., et al. (2017). Longitudinal assessment of cancer-related cognitive
impairment (CRCI) up to six-months post-chemotherapy with multiple
cognitive testing methods in 943 breast cancer (BC) patients and controls.
J. Clin. Oncol. 35, 10014–10014. doi: 10.1200/JCO.2017.35.15_suppl.10014
Jiang, F., Deng, L., Zhang, L., Cai, Y., Cheung, C. W., and Xia, Z. (2020).
Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-
19). J. General Internal Med. 35, 1545–1549. doi: 10.1007/s11606-020-
05762-w
Koster, E. H. W., Hoorelbeke, K., Onraedt, T., Owens, M., and Derakshan, N.
(2017). Cognitive control interventions for depression: A systematic review of
findings from training studies. Clin. Psychol. Rev. 53, 79–92. doi: 10.1016/j.cpr.
2017.02.002
Lai, A., Pasea, L., Banerjee, A., Denaxas, S., Katsoulis, M., Chang, W. H., et al.
(2020). Estimating excess mortality in people with cancer and multimorbidity
in the COVID-19 emergency. medRxiv [preprint]. doi: 10.13140/RG.2.2.34254.
82242
Land, L. H., Dalton, S. O., Jørgensen, T. L., and Ewertz, M. (2012). Comorbidity
and survival after early breast cancer. A review. Crit. Rev. Oncol. Hematol. 81,
196–205. doi: 10.1016/j.critrevonc.2011.03.001
Lee, M. K., Varzi, L. A., Chung, D. U., Cao, M., Gornbein, J., Apple, S. K., et al.
(2015). The Effect of Young Age in Hormone Receptor Positive Breast Cancer.
BioMed Res. Int. 2015, 1–6. doi: 10.1155/2015/325715
Liu, Y., Jiang, T., and Shi, T. (2020). The Relationship Among Rumination, Coping
Strategies, and Subjective Well-being in Chinese Patients With Breast Cancer: A
Cross-sectional study. Asian Nurs. Res. 2020:S1976131720300505. doi: 10.1016/
j.anr.2020.07.005
Maajani, K., Jalali, A., Alipour, S., Khodadost, M., Tohidinik, H. R., and Yazdani, K.
(2019). The Global and Regional Survival Rate of Women With Breast Cancer:
A Systematic Review and Meta-analysis. Clin. Breast Cancer 19, 165–177. doi:
10.1016/j.clbc.2019.01.006
Moghanibashi-Mansourieh, A. (2020). Assessing the anxiety level of Iranian
general population during COVID-19 outbreak. Asian J. Psychiat. 51:102076.
doi: 10.1016/j.ajp.2020.102076
Maringe, C., Spicer, J., Morris, M., Purushotham, A., Nolte, E., Sullivan, R., et al.
(2020). The impact of the COVID-19 pandemic on cancer deaths due to delays
in diagnosis in England, UK: a national, population-based, modelling study.
Lancet Oncol. 21, 1023–1034.
Nafissi, N., Khayamzadeh, M., Zeinali, Z., Pazooki, D., Hosseini, M., and Akbari,
M. E. (2018). Epidemiology and Histopathology of Breast Cancer in Iran versus
Other Middle Eastern Countries. Middle East J. Cancer 9:42130. doi: 10.30476/
mejc.2018.42130
Nolen-Hoeksema, S. (2000). The role of rumination in depressive disorders and
mixed anxiety/depressive symptoms. J. Abnormal Psychol. 109, 504–511. doi:
10.1037/0021-843X.109.3.504
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